Heparin Market to Grow with a CAGR of 5.96% through 2028
Expanding applications in areas such as cancer
treatment and medical device coatings are expected to drive the Global Heparin
Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Global
Heparin Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2028”, the Global Heparin Market stood at USD 6.48 billion
in 2022 and is anticipated to grow with a CAGR of 5.96% in the forecast period,
2024-2028. The global heparin market, a vital component of the pharmaceutical
and healthcare sector, is experiencing significant growth, fueled by various
market drivers. Heparin, a natural anticoagulant, plays a pivotal role in
preventing and treating thrombotic disorders, making it indispensable in modern
medicine. This article explores the key market drivers that are propelling the
growth of the global heparin market. One of the primary drivers behind the
growth of the global heparin market is the rising prevalence of thrombotic
disorders worldwide. Conditions such as deep vein thrombosis (DVT), pulmonary
embolism (PE), and arterial thrombosis are becoming increasingly common,
contributing to a surge in the demand for anticoagulant therapies. Heparin,
available in various forms, including unfractionated heparin (UFH) and
low-molecular-weight heparin (LMWH), remains a cornerstone in the treatment and
prevention of these disorders.
The global burden of cardiovascular diseases, in
particular, has been on the rise, necessitating the use of heparin-based
therapies. Cardiovascular diseases are a leading cause of mortality globally,
and heparin's anticoagulant properties play a crucial role in managing these
conditions. As the incidence of cardiovascular diseases continues to increase,
so does the demand for heparin products. Another significant driver of the
heparin market is the aging population in many countries. As individuals age,
they become more susceptible to thrombotic disorders, further increasing the
need for anticoagulant therapies like heparin. Elderly individuals often
require long-term management of thrombotic conditions, and heparin remains a
preferred choice due to its proven efficacy. The demographic shift toward an
older population is particularly pronounced in developed countries, where
healthcare infrastructure is well-established. Consequently, these regions
witness higher utilization of heparin products. This trend is expected to
persist in the coming years, driving the growth of the global heparin market.
The global increase in surgical procedures, ranging
from complex open-heart surgeries to minimally invasive procedures, has
substantially boosted the demand for heparin. Surgeons frequently use heparin
as a prophylactic and therapeutic agent during surgeries to prevent blood clot
formation. Heparin's ability to prevent clotting is crucial in reducing the
risk of complications during and after surgery, such as deep vein thrombosis
and pulmonary embolism. Moreover, the advancements in surgical techniques have
led to a greater number of surgeries being performed, including orthopedic
procedures, cardiac surgeries, and vascular surgeries. These surgical
interventions often necessitate the use of heparin to maintain the patient's
overall well-being, further driving the market.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Heparin Market.”
The Global Heparin Market is segmented into Product,
Type, Application, Regional Distribution, And Company. Based on the Type, the Low Molecular Weight Heparin
(LMWH) emerged as the dominant segment in the global market for Global Heparin
Market in 2022. LMWH has a well-established track record for its efficacy and
safety in preventing and treating thrombotic disorders, such as deep vein
thrombosis (DVT) and pulmonary embolism (PE). Its use has been extensively
studied and documented in clinical practice, making it a trusted choice for
healthcare professionals. Also, LMWH is typically administered subcutaneously,
which is less invasive and more convenient than intravenous administration
required for unfractionated heparin (UFH). This ease of administration makes
LMWH more accessible for both healthcare providers and patients.
Based on the Application, the Medical Technology
segment emerged as the dominant player in the global market for Global Heparin
Market in 2022. CAD is one of the most common cardiovascular diseases globally,
affecting millions of individuals. It is a leading cause of morbidity and
mortality, making it a significant healthcare concern. The high prevalence of
CAD results in a substantial demand for anticoagulant therapies like heparin. CAD
often requires invasive procedures such as angioplasty and coronary artery
bypass grafting (CABG). Heparin is a critical component of these procedures,
used to prevent clot formation during interventions. The widespread adoption of
these treatments contributes to the consistent demand for heparin in CAD
management.
Based on the End User, the Hospitals & Clinics segment
emerged as the dominant player in the global market for Global Heparin Market
in 2022. Hospitals are
the primary settings for complex medical procedures and surgeries. In these
facilities, heparin is extensively used as an anticoagulant during surgeries to
prevent clot formation, especially in high-risk procedures like open-heart
surgery, vascular surgery, and orthopedic surgeries. This high demand for
heparin is directly associated with the broad spectrum of medical interventions
undertaken in hospitals. Hospitals provide inpatient care for a wide range of
medical conditions, including those requiring anticoagulant therapy. Patients
admitted to hospitals often require immediate and continuous medical attention,
making heparin administration an integral part of their treatment. This results
in a sustained demand for heparin in hospital settings.
North America emerged as the dominant player in the Global
Heparin Market in 2022, holding the largest market share. North America,
particularly the United States and Canada, has consistently maintained high
levels of healthcare expenditure. This substantial healthcare investment allows
for greater access to advanced medical treatments, including heparin-based
therapies. Patients in the region have access to a wide range of medical
services, contributing to the high demand for heparin products. North America
has a relatively high prevalence of thrombotic disorders, including deep vein
thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis. These
conditions require anticoagulant treatments like heparin, which results in a
significant market share for heparin products in the region.
Major companies operating in Global Heparin Market are:
- GlaxoSmithKline plc (GSK)
- Pfizer Inc.
- Sanofi AG
- Dr. Reddy’s Laboratories Ltd.
- Aspen Holdings
- B. Braun Medical Inc.
- Fresenius SE & Co. KGaA
- Novartis AG
- B. Braun Medical Inc.
- Sandoz (Novartis AG)
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global
Heparin Market is poised for significant growth in the coming years.
Anticipated factors driving this expansion include the increasing prevalence of
thrombotic disorders, a growing aging population, and rising demand for
anticoagulant therapies. Heparin's established efficacy in preventing and
treating conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE)
reinforces its importance in modern medicine. Additionally, expanding
applications of heparin in areas like cancer therapy and medical device
coatings are expected to fuel market growth. Regulatory initiatives aimed at
ensuring product safety and quality are likely to enhance consumer confidence
and drive demand. Advancements in heparin production and delivery systems, as
well as ongoing research into its therapeutic properties, are anticipated to
open new opportunities in the market.” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“Heparin Market - Global Industry Size, Share,
Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Low Molecular
Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH), By
Application (Venous Thromboembolism, Coronary Artery Disease, Renal Impairment,
Atrial Fibrillation, Others), By Route
of Administration (Intravenous, Subcutaneous), By End Use (Hospitals &
Clinics, Ambulatory care Centres, Others) By Region and Competition”, has evaluated
the future growth potential of Global Heparin Market and provides statistics
& information on market size, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Heparin Market Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com